Anyone going through cancer treatment may reach the moment of hearing that a drug is no longer working — that the tumor has become resistant. This is especially common when colorectal cancer has spread to the liver or other organs: a medicine that worked well at first can gradually lose its effect, and the tumor may start to grow again. When several standard chemotherapy regimens have been used one after another and the intervals between them keep getting shorter, an oncologist may gently say that the next drug, too, might not hold for long. Hearing this is deeply shaking, and it is completely natural to think, 'Maybe a larger hospital has another option.'
It helps to know that standard cancer treatment is largely guided by national and international clinical guidelines. For the same stage and the same tumor genetics, the basic framework of treatment recommended at a regional hospital and at a major center is often not very different. So it is not accurate to assume that a bigger-city hospital simply hands out 'better drugs.'
That said, larger cancer centers can genuinely offer some things that differ. The most important is access to clinical trials. When standard options are running out, the question of whether you qualify for a study — one testing a not-yet-approved drug or a new combination — can become a meaningful path forward. Another is comprehensive molecular profiling (next-generation sequencing, NGS). If a specific tumor alteration is found (for example MSI-High, BRAF, or HER2), it may open the door to targeted therapy or immunotherapy, and the breadth of testing and the experience in interpreting it can change what is offered. Multidisciplinary tumor boards, where several specialties discuss a case together, are also often more active at larger centers.
Seeking a second opinion is not a sign of distrust in your doctor. Most oncologists regard it as normal for patients to want another expert view, and will prepare a referral letter along with imaging and pathology records. Because an appointment at a major center can take weeks, it is safest to continue treatment where you are now while you schedule that consultation in parallel.
Weighing whether to transfer or to stay is easier when you consider a few things together: the realistic chance of a new treatment or trial, the burden of travel and your physical stamina, where you would go in an emergency, and — above all — the patient's own wishes. In many cases, you can confirm a direction at a major center and then continue the actual chemotherapy at a closer hospital through shared care. Bringing recent imaging discs, pathology results, a record of the drugs used and how the tumor responded, and up-to-date blood work makes the consultation far smoother.
Most of all, this decision comes not from 'giving up' but from a wish to explore every possible path to the end. Whatever you choose, you are doing your best, and if things do not turn out as hoped, it is not something to blame yourself for.
This article is for general information only and does not replace examination or advice from your care team. Please make all decisions about treatment direction and choice of hospital in full discussion with your own medical team.